Compare NNVC & GRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNVC | GRF |
|---|---|---|
| Founded | 2005 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.2M | 39.9M |
| IPO Year | 2008 | N/A |
| Metric | NNVC | GRF |
|---|---|---|
| Price | $1.45 | $10.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 392.1K | 4.0K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.70% |
| EPS Growth | ★ 10.00 | N/A |
| EPS | N/A | ★ 1.16 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.85 | $9.60 |
| 52 Week High | $2.23 | $11.85 |
| Indicator | NNVC | GRF |
|---|---|---|
| Relative Strength Index (RSI) | 66.85 | 49.38 |
| Support Level | $1.45 | $9.69 |
| Resistance Level | $1.47 | $10.64 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 96.71 | 52.84 |
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.